- Moss Genomics (MOSS) has launched its gut microbiome test
- The gut microbiome is home to trillions of microbes that directly influence a person’s mood, how they digest food and how their immune system responds to infections or allergens
- The report includes a comprehensive and in-depth analysis of the types and amount of microorganisms present, gut microbiome harmony, disease related microbes insight, and obesity risk
- Moss Genomics (MOSS) opened trading at $0.15
Moss Genomics (MOSS) has launched its gut microbiome test.
The gut microbiome is home to trillions of microbes that directly influence a person’s mood, how they digest food and how their immune system responds to infections or allergens.
The report includes a comprehensive and in-depth analysis of the types and amount of microorganisms present, gut microbiome harmony, disease related microbes insight, and obesity risk.
Moss also unveiled a suite of genetic reports which serve to complement its main products that further explore and understand customer’s genetic data. The first report will focus on mental health.
The company’s president, Michelle Lee, explained that actionable health data derived from the gut microbiome test can help customers overcome chronic gut health related problems.
“Our new gut microbiome test provides an affordable low-cost entry for new customers to our brand. Our mental health report is part of a series of reports we plan to release over the coming months as we continue to develop and bring to market new and innovative solutions that leverage of our genetic and microbiome sequencing capabilities to improve human health.”
Moss Genomics Inc. (MOSS) is a consumer genomics company that offers personalized health, anti-aging, and wellness offerings guided by genomic, microbiome, and epigenome data.
Moss Genomics (MOSS) opened trading at $0.15.